Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
Chandler, US
510 (est)

Key People at Insys Therapeutics

Michael L. Babich

Michael L. Babich

Larry Dillaha

Larry Dillaha

Darryl S. Baker

Darryl S. Baker


Insys Therapeutics Locations

Chandler, US

Insys Therapeutics Metrics

Insys Therapeutics Summary

Founding Date


Market capitalization

$800 M

Closing share price


Insys Therapeutics Market Value History

Insys Therapeutics News

Insys Therapeutics Company Life